Cytokinetics Inc
NASDAQ:CYTK
Cytokinetics Inc
Revenue
Cytokinetics Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Cytokinetics Inc
NASDAQ:CYTK
|
Revenue
$7.5m
|
CAGR 3-Years
-49%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
-13%
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$29.5B
|
CAGR 3-Years
5%
|
CAGR 5-Years
4%
|
CAGR 10-Years
5%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
13%
|
CAGR 5-Years
15%
|
CAGR 10-Years
19%
|
See Also
What is Cytokinetics Inc's Revenue?
Revenue
7.5m
USD
Based on the financial report for Dec 31, 2023, Cytokinetics Inc's Revenue amounts to 7.5m USD.
What is Cytokinetics Inc's Revenue growth rate?
Revenue CAGR 10Y
-13%
Over the last year, the Revenue growth was -92%. The average annual Revenue growth rates for Cytokinetics Inc have been -49% over the past three years , -25% over the past five years , and -13% over the past ten years .